New: Spectronaut® 19
Unlock Your Data's True Story
New: Spectronaut® 19
Unlock Your Data's True Story
The novel particle-based P2 Plasma Enrichment System achieves the highest reported proteome enrichment with greater reproducibility than any other protein corona-based workflow. The optimized single-well sample preparation, combined with optimized particle surface, stabilizes the labile protein corona and provides exceptional quantitative accuracy.
The brochure provides an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.
Poster 3923/19 presented at AACR 2022
Presenter: Jakob Vowinckel
Session: PO.CH03.01 Proteomics, Signaling Networks, and Biomarker Discovery
Date: April 13
Decaris M, Rexhepaj M, Vowinckel J, Dupuis N, Wei Y, Hariri LP, Greenland JR, Chapman HA, Lee JS, Wolters PJ, Turner S. ATS Journals.
Urine represents an understudied source of biomarkers for interstitial lung disease. Noninvasive biomarkers that reliably predict disease progression and treatment response can benefit clinical trials. Here we applied global quantitative proteomics for biomarker discovery in urine samples from IPF patients and subsequently validated potential candidates using orthogonal ELISA assays.
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
